FHIT gene therapy prevents tumor development in Fhit-deficient mice
AUTOR(ES)
Dumon, Kristoffel R.
FONTE
The National Academy of Sciences
RESUMO
The tumor suppressor gene FHIT spans a common fragile site and is highly susceptible to environmental carcinogens. FHIT inactivation and loss of expression is found in a large fraction of premaligant and malignant lesions. In this study, we were able to inhibit tumor development by oral gene transfer, using adenoviral or adenoassociated viral vectors expressing the human FHIT gene, in heterozygous Fhit+/− knockout mice, that are prone to tumor development after carcinogen exposure. We therefore suggest that FHIT gene therapy could be a novel clinical approach not only in treatment of early stages of cancer, but also in prevention of human cancer.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=30656Documentos Relacionados
- The tumor spectrum in FHIT-deficient mice
- Muir–Torre-like syndrome in Fhit-deficient mice
- Interferon-β gene therapy inhibits tumor formation and causes regression of established tumors in immune-deficient mice
- Moloney murine leukemia virus-induced lymphomas in p53-deficient mice: overlapping pathways in tumor development?
- Restored insulin-sensitivity in IRS-1–deficient mice treated by adenovirus-mediated gene therapy
